PA
FULC icon

PharVision Advisers’s Fulcrum Therapeutics FULC Stock Holding History

PharVision Advisers’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,868
Closed -$220K – 801
2025
Q3 		$220K Buy
+23,868
New +$173K 0.12% 429

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PharVision Advisers's FULC Position: Q4 2025 in Review

PharVision Advisers sold out of Fulcrum Therapeutics (FULC) in Q4 2025, closing a stake of 23,868 shares — an estimated $220K sold.

PharVision Advisers first reported a position in FULC in Q3 2025 and held it in 1 quarter. The position peaked at $220K in Q3 2025. 172 funds tracked by Wall St. Rank hold FULC as of Q4 2025.

  • PharVision Advisers reported no remaining Fulcrum Therapeutics position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 23,868 Fulcrum Therapeutics shares in Q4 2025, an estimated $220K.
  • PharVision Advisers first reported a position in Fulcrum Therapeutics in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Fulcrum Therapeutics position peaked at $220K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.